Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1

Takeda announced that oveporexton (Orzeyful) CIV is now available in the US by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. This is the first and only orexin agonist for this indication.

Orzeyful selectively stimulates the orexin receptor 2 (OX2R) to restore signaling and address the underlying orexin deficiency associated with NT1. By activating OX2Rs, Orzeyful promotes wakefulness and reduces abnormal rapid eye movement-sleep like phenomena, including cataplexy.

“Clinical trials showed Orzeyful improved the full range of symptoms, and now we can bring those results into real-world practice,” said Emmanuel Mignot, MD, PhD, the principal US investigator in the Orzeyful phase 3 program. “Using Orzeyful to target the underlying cause of narcolepsy type 1 is a welcome and exciting development in sleep medicine. I can now start a new conversation with my patients about their symptoms and how using this new treatment approach may make a real difference for them.”

Holistic Treatment

Notably, this new option targets the underlying orexin deficiency to treat the disease holistically rather than merely individual symptoms.

“We work for decades toward the defining moments that have the potential to make a real difference for patients,” said Rhonda Pacheco, president of Takeda’s US Business Unit. “Bringing Orzeyful, a first-in-class medicine, to people living with narcolepsy type 1 in the US is one of those moments. We are incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed Orzeyful.”

Now Available

Orzeyful is available by prescription from a licensed health care providers and will be dispensed across the US through Accredo Specialty Pharmacy. Takeda does offer patient support programs to help eligible adult patients who are prescribed Orzeyful.

“Living with narcolepsy type 1 is an ongoing struggle to keep it together—from scheduling naps and anticipating sleep attacks to figuring out how to be present as a mom and a professional,” said Emily P, a clinical trial participant with NT1. “With Orzeyful, I feel more confident planning my day because my narcolepsy has become more manageable.”

Reference

1. Takeda launches ORZEYFUL™ (oveporexton), the first and only medicine of Its kind for narcolepsy type 1 now available in the United States. News release. November 12, 2026. Accessed November 12, 2026. https://pressreleasehub.pa.media/article/takeda-launches-orzeyful-oveporexton-the-first-and-only-medicine-of-its-kind-for-narcolepsy-type-1-now-available-in-the-united-states-89101.html